Menu
/REGISTER
Montecito
Tolman Wiker
Pac Premier
Farmers merchants
Loading...
You are here:  Home  >  Biotech  >  Current Article

Biotech giant Amgen bails on brain research

By   /   Friday, November 1st, 2019  /   No Comments

    Print       Email
Amgen announced its exit from neurology research as sales slumped in its third quarter, while higher net income and stock buybacks propelled earnings per share up 14 percent. Despite the initial success of its migraine treatment Aimovig, the Thousand Oaks biotech giant announced its intention to call off early forays into neuroscience research, shifting its…

Subscribe

    This article is only available to Business Times subscribers
  • Subscribers: LOG IN or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.
    Print       Email

Leave a Reply

Your email address will not be published. Required fields are marked *

You might also like...

Apeel adding facilities in Mexico, Peru and Netherlands

Read More →